rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BMY
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors
      5h agoMarketWatchBMY
      Bristol-Myers Squibb: 3 Key Takeaways for Long-Term Investors
      7h agoYahoo FinanceBMY
      Bristol Myers Squibb Says KarXT Reduces Hallucinations and Delusions In Preliminary Alzheimer's Trials
      10h agoBenzingaBMY
      Bristol unveils late-stage data on asset for Alzheimer's psychosis

      Bristol Myers Squibb says KarXT cuts Alzheimer’s psychosis scores 12.0 points at 12 weeks; preliminary 52-week data show a 5.1-point drop.

      10h agoSeeking AlphaBMY
      Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows
      12h agoReutersBMY
      Bristol Myers Stock's Dividends Couldn't Close The Gap
      14h agoYahoo FinanceBMY
      Erasca Partners With Bristol Myers Squibb to Evaluate ERAS-0015 Combination Treatment for Pancreatic Cancer
      15h agoYahoo FinanceERASBMY
      'It's not a birthright': Bristol Myers Squibb CEO warns America about vaccines and losing its measles elimination | Fortune

      On the day the U.S. lost its measles-elimination status, BMS CEO Chris Boerner warned against “policies that don’t” protect the drug ecosystem.

      19h agoFortuneBMY
      How Investors Are Reacting To Bristol Myers Squibb (BMY) R&D Leadership Overhaul
      Nov 15Yahoo FinanceBMY
      Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.
      Nov 14Yahoo FinanceBMY
      PAID POST by Bristol Myers Squibb — The Alzheimer’s Disease Symptoms You Can’t See on a Scan

      Seeing and hearing things that aren’t really there. Paranoia. Distress. Two daughters share how they managed their mothers’ behavioral changes from Alzheimer’s disease while keeping the core element of their relationship — love — intact.

      Nov 13The New York TimesBMY
      Bristol Myers Squibb (BMY) Stock Looks Below Fair Value Following A 41% Run

      Bristol-Myers Squibb has quietly turned in a strong share price run over the past few years, helped by fresh data for key therapies and a solid pipeline story. With the stock around US$62.91 at the last close, the real question for you is whether that level is backed up by the cash the business can generate over time. Over the past 3 years the stock has returned about 40.5%, which puts real pressure on the cash flow outlook to justify the step up in market value. Recent trial results for...

      Nov 12Yahoo FinanceBMY
      Bristol Myers research chief to depart in ‘evolution’ of company’s structure
      Nov 12Yahoo FinanceBMY
      Bristol Myers to merge scientific, clinical teams under new R&D structure
      Nov 12ReutersBMY
      Bristol Myers Squibb unifies R&D under new leadership
      Nov 12Investing.comBMY
      Bristol Myers to operate R&D under one organization

      Bristol Myers Squibb (BMY) plans to establish a unified research & development organization next year under the current development head. Read more here.

      Nov 12Seeking AlphaBMY
      Our Bristol Myers Squibb Stock Pick Is Up 35%. It’s Still a Good Bet in Healthcare.

      The stock is still attractive trading at 10 times forward earnings.

      Nov 12Barron'sBMY
      A 72-Year-Old With $500,000 in PepsiCo, Nike and Bristol Myers Squibb Collects $1,729 a Month in Dividends. How Safe Is Each Check?
      Nov 11Yahoo FinanceBMYNKE
      Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
      Nov 10MarketWatchBMY
      Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?

      Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

      Nov 9The Globe and MailBMY
      Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors
      Nov 7Yahoo FinanceBMY
      Bristol Myers Squibb director Julia Haller sells $240,578 in stock
      Nov 7Investing.comBMY
      Bristol says long-term Camzyos data buoys treatment in children (BMY:NYSE)

      Bristol Myers Squibb reports 56-week Camzyos phase 3 data in children with obstructive HCM, showing LVOT improvement after placebo switch. Read more here.

      Nov 6Seeking AlphaBMY
      Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors
      Nov 6MarketWatchBMY
      Bristol Myers Squibb presents 56-week Camzyos trial data
      Nov 6Investing.comBMY
      Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?
      Nov 6Yahoo FinanceBMY
      Bristol Myers Squibb (BMY) Expands Neuroscience Push With Multi Year AI Alliance
      Nov 6Yahoo FinanceBMY
      Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Rally Already Priced In?

      Bristol-Myers Squibb (BMY) is back in the spotlight after the FDA granted accelerated approval for ZENBEXUS in multiple myeloma, along with fresh positive trial updates in lung cancer and multiple sclerosis. Recent moves suggest investors are rewarding this stream of drug updates. The share price is up 4.02% over 1 day, 9.15% over 30 days and 20.07% year to date, while the 1-year total shareholder return of 44.28% points to momentum that has been building rather than fading. Scan how...

      Nov 5Yahoo FinanceBMY
      What Changed In Bristol Myers Squibb's Story?
      Nov 5Yahoo FinanceBMY
      Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
      Nov 4MarketWatchBMY
      BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)
      Nov 4Seeking AlphaBNTXBMY
      Polaris Rx Selected by Bristol Myers Squibb to Dispense ZENBEXUS™ (iberdomide), the First FDA-Approved CELMoD Therapy for Multiple Myeloma
      Nov 4Yahoo FinanceBMYPII
      Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

      Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

      Nov 4Yahoo FinanceBMY
      What Could Derail Bristol Myers Squibb Stock?
      Nov 3Yahoo FinanceBMY
      BioNTech Lifts Outlook Boosted by Cancer Drug Milestone Payments
      Nov 3BloombergBNTXBMY
      5 must-read analyst questions from Bristol-Myers Squibb’s Q3 earnings call
      Nov 2Yahoo FinanceBMY
      Bristol Myers Squibb Stock: Is Wall Street Bullish or Bearish?
      Nov 2BarchartBMY
      43 ETFs Add to Bristol-Myers Squibb (BMY) on Oct. 29
      Nov 2Yahoo FinanceBMY
      What Bristol Myers Squibb Stock's Earnings Beat Means For Shareholders

      Bristol-Myers Squibb reported Q3 2026 revenue of US$13.07b and net income of US$2.16b, beating analyst expectations and prompting higher full-year sales guidance, while EPS guidance was updated after an 11.57% earnings surprise. The firm paired this beat with strong growth portfolio performance, new multiple myeloma approvals, and encouraging late-stage data in oncology and neuroscience, which tightened the link between current cash generation and its next wave of pipeline-driven...

      Oct 31Yahoo FinanceBMY
      Bristol Myers Squibb (BMY) Reports Positive Phase 2 Pumitamig Lung Cancer Data
      Oct 31Yahoo FinanceBMY
      Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (NYSE:BMY)

      Bristol-Myers Squibb is downgraded to Hold as its current valuation appears optimistic ahead of looming patent cliffs. Read more on BMY stock here.

      Oct 30Seeking AlphaBMY
      Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue
      Oct 30BloombergBMYMRK
      BofA raises Bristol-Myers Squibb stock price target to $67
      Oct 30Investing.comBMY
      How Bristol Myers’s CEO Challenged the Company’s Managers
      Oct 30WSJBMY
      Truist reiterates Buy on Bristol-Myers Squibb stock on Q3 beat
      Oct 30Investing.comBMYTFC
      Bristol Myers Squibb Q3 Earnings Call Highlights
      Oct 30Yahoo FinanceBMY
      Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains
      Oct 29MarketWatchBMY
      Bristol-Myers Squibb Co (BMY) (Q3 2026) Earnings Call Highlights: Revenue Climbs 7% to $13. ...
      Oct 29Yahoo FinanceBMY
      Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction | The Motley Fool

      Bristol Myers Squibb’s adjusted earnings fell 17%, but the company raised its sales outlook. Here’s why the drop reflects a pipeline refill, and what its newer drugs need to deliver next.

      Oct 29The Motley FoolBMY
      What's Going On With Bristol-Myers Squibb Stock Thursday? - Bristol-Myers Squibb (NYSE:BMY)
      Oct 29BenzingaBMY

      This is the newest page. Registered accounts read further back.